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Background: The overall incidence of poor ovarian response in IVF cycles has been reported to be between 9 and
24 %. The management of these patients remains a significant challenge in assisted reproduction. The aim of the
present study was to evaluate the effect of myo-inositol (MI) on ovarian function in poor responders undergoing ICSI.
Methods: The study is a prospective controlled observational trial, that involved 72 poor responders included in an ICSI
program and divided into two groups; group A: 38 patients who have been assuming MI (4 g) + folic acid (FA) (400 μg) for
the previous 3 months before the enrollment day; group B: 38 patients assuming FA (400 μg) alone for the same period.
COH was carried out in the same manner in the two groups. The main goal was the assessment of oocytes retrieved
number and quality; secondary endpoints were the Ovarian Sensitivity Index (OSI: n° oocytes retrieved/total Gonadotropins
units × 1000), oestradiol levels on the day of hGC, fertilization rate, implantation rate, ongoing pregnancy rate.
Results: There was no significant difference between the two groups regarding oestradiol level, but total rec-FSH units
were significantly lower (p = 0.004) and M2 oocytes rate significantly higer (p = 0.01) in group A. The ovarian sensitivity
index was higher, reaching a statistical significance (p < 0.05), in the group of patients pre-treated with MI, showing an
improvement in ovarian sensibility to gonadotropin.
Conclusions: Our results suggest that MI therapy in poor responders results in an increased of the number of oocytes
recovered in MII and of the gonadotropin Ovarian Sensitivity Index (OSI), suggesting a MI role in improving ovarian
response to gonadotropins. Therefore MI seems to be helpful in “poor responders” undergoing IVF cycles.
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It is well known that advanced reproductive age patients
exhibit worst response to ovulation induction because
female age is the main factor that affects the number of
retrieved oocyte and gonadotropins set [1].
In addition to a quantitative reduction of their oocyte
cohorts, poor ovarian responder patients (PORs) present
a high risk of implantation failure that may suggest a
compromised oocyte quality [2].
The overall incidence of poor ovarian response has
been reported to be between 9 and 24 % [3, 4]. A variety
of regimens have been employed, including the use of* Correspondence: francescacaprio@infinito.it
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releasing hormone (GnRH) agonists or antagonists, flare
regimes, sequential protocols, adjunctive growth hormone,
dehydroepiandrosterone adjuvant therapy, minimal ovar-
ian stimulation with clomiphene citrate, and natural cycle
IVF [5–8]. However, the ideal stimulation regimen for
poor responders is currently unknown. In addition, there
is insufficient evidence to support the use of specific inter-
ventions to improve IVF treatment outcomes in poor
responders. The Cochrane review of poor responder in-
terventions concluded that no particular treatment of-
fered clear benefit, or could be recommended [4]. The
management of poor responders therefore remains a
significant challenge in assisted reproduction.ticle distributed under the terms of the Creative Commons Attribution License
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erroneously included among vitamins for a long time,
while it is a vitamin-factor of B group.
Many studies support the notion that myo-inositol
(MI), an inositol isoform, is one of the precursors for the
synthesis of phosphatidylinositol polyphosphates (PIPs).
PIPs are key biomolecules considered part belonging to
the signal transduction system known to be involved in
the regulation of several cellular functions [9]. Infact, MI
plays a crucial role in signal transduction, cell morpho-
genesis and cytogenesis, it is involved in cell membrane
formation, lipid synthesis and cell growth [10].
The role of inositol in the streamlining of ovulatory
process has been widely defined in patients with reduced
sensitivity to insulin, as far as the inositol’s insulin sensi-
tizing action [11]. Recently it has been hypothesized that
inositol could have a different way of action on different
cell kinds, apart from the insuline-resistance reduction
mechanism. Indeed, at ovarian level MI has been shown
to be crucial for the FSH signaling and it is involved in
oocyte maturation and embryo development. Recently,
an international consensus conference, further confirmed
that, during IVF program, MI pretreatment is able to im-
prove the oocyte and embryo quality [12, 13].
A previous study has demonstrated that supplementa-
tion with inositol can reduce the oxidative stress caused
by different agents through the induction of natural anti-
oxidant defenses by increasing superoxide dismutase
(sod) and catalase (cat) levels and intracellular content
of glutathione (GSH) [14].
Noteworthy, the data discussed in the consensus manu-
script highlighted that MI pre-treatment is effective on
both PCOS and healthy women undergoing controlled
ovarian hyperstimulation.
On this basis, inositol is becoming part of clinical prac-
tice in the treatment of both PCO and not PCO women,
both for its insulin-sensitizing activity and its effect on oo-
cyte maturation and quality [15].
Nevertheless, data are missing on the use of MI in
women defined poor responders undergoing ovarian stimu-
lation for ICSI cycle. Therefore, the aim of the present
study was to provide evidence on the matter and eventually
open new research line.
Materials and methods
Patients
The study is a prospective controlled observational trial,
that involved 76 women included in an ICSI program at
the IVF Unit of the Second University of Naples between
November 2013 and November 2014. All the women
were poor-responder, according to the Bologna Criteria,
defined by the Consensus Group for the European Soci-
ety for Human Reproduction and Embryology (ESHRE)
to help assigning more uniform patient groups in clinicaltrials [16]. Poor responders were classified with at least
two of the three following criteria: (I) advanced maternal
age (>40 years) or any other risk factor for POR; (II) a
previous POR (<3 oocytes with a conventional ovarian
stimulation protocol); and (III) an abnormal ovarian re-
serve test (ORT).
According to our experience we have considered the
ovarian reserve test altered in case of AFC <5–7 follicles
or AMH <1.5 ng/ml.
The selection criteria for this study were as follows:
women of 30 to 42 years old, with normal ovulatory cy-
cles of 24 to 35 days in length, FSH value <15 IU/mL,
body mass index (BMI) between 18 and 25 kg/m2 and
absence of any endocrine and metabolic disorders such
as polycystic ovary syndrome, hyperprolactinemia, dia-
betes and thyroid dysfunction.
Patients were excluded from this study if they were found
to have any significant pelvic pathology such as hydrosal-
pinx, uterine anomaly, advanced endometriosis of stage III
to IV or fibroids with uterine cavity distortion. Patients
with a partner with a severe oligo-astheno-teratozoospermia
(OAT) or azoospermia were excluded, as well.
Patients satisfying all the inclusion criteria were included
in the study and divided into two groups: group A con-
sisted of 38 patients who have been assuming 4 g of MI +
400 μg of folic acid (Inofert, Italfarmaco Spa, Milan) every
day for the previous 3 months before the enrollment day;
group B consisted of 38 patients assuming 400 μg of folic
acid (Folidex, Italfarmaco Spa, Milan) alone every day for
the same period. The MI dosage was evaluated according
to a previous study that investigated the effect of a sup-
plementation with MI and melatonin on oocyte quality
in women who failed to conceive in previous in vitro
fertilization cycles for poor oocyte quality [17].Stimulation protocol
Patients underwent controlled ovarian hyperstimulation
(COH) with the use of a GnRH antagonist protocol.
COH was carried out in an identical manner in the two
groups, with 300 IU of recombinant FSH (Gonal-F, Merck-
Serono, Switzerland), from day 2 or 3 of the cycle. Daily
injections of a GnRH antagonist (Cetrotide 0.25 mg sc,
Merck-Serono, Switzerland) were administered to prevent
premature ovulation by using the flexible antagonist proto-
col, according to a personalized regimen, from the day the
leading follicle reached 14 mm in diameter until the day of
hCG injection. Ovulation induction was monitored by
vaginal ultrasound and hormonal assessment every second–
third day. When at least two follicles had reached a diameter
of 18 mm, a single i.m. bolus of 10.000 IU of hCG (Gonasi
HP 5000; IBSA, Rome, Italy) was administered. Transvaginal
follicular aspiration was performed 34–36 h after hCG
administration.
Table 1 Baseline characteristics
Group A Group B P
(35 patients) (30 patients)
Age (years) 33.2 ± 2.8 33.9 ± 3.1 NS
Body mass index (kg/m2) 23.3 ± 2.3 24.2 ± 2.0 NS
Time of infertility (years) 1.9 ± 1 2.2 ± 0.5 NS
Day-3 FSH (IU/mL) 7.4 ± 1.9 6.9 ± 2.3 NS
AMH (ng/mL) 2.3 ± 1.1 2.8 ± 1.8 NS
Data are presented as mean ± SD (range). P not significant (NS) for all
comparisons (P > 0.05)
Table 2 Stimulation data
Group A Group B p
Oestradiol level 1129 ± 366 1016 ± 462 n.s
rec-FSH (U.I./mL) 1975 ± 298 2212 ± 312 <0.05
n° oocytes retrieved 3.65 ± 1.32 3.39 ± 1.38 n.s
O.S.I. 1.88 ± 0.81 1.54 ± 0.65 <0.05
n.s. not significant, O.S.I. ovarian sensitivity index
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with principles of the Helsinki Declaration of 1975, using
routine clinical practice procedures usually performed
during IVF cycles; such procedures did not involve add-
itional risks to the patients and all the medical decisions
concerning individual patients were not affected by the
study. The Institutional Review Board approved the proto-
col and all patients gave a written informed consent before
entering in the study.
Laboratory procedures
Oocytes were cultured in Petri dishes in IVF-20 (Vitrolife,
Göteborg, Sweden) at 37 °C in a humidified 5 % carbon di-
oxide/95 % air environment. The semen was processed
with 80 % Percoll (Sigma Chemical Company, St. Louis,
MO) discontinuous gradient centrifugation at 800 g for
15 min. ICSI procedures have been described in detail
previously [18, 19] and were performed 4–6 h after oocyte
retrieval. After IVF, the resulting embryos were cultured
in IVF-20 at 37° under 5 % carbon dioxide in air. Embryos
were graded by morphological analysis: grade 1, blasto-
meres with 5–10 % extracellular fragmentation; grade 2,
10–20 % extracellular fragmentation; grade 3, 20–30 %
extracellular fragmentation; grade 4, >30 % blastomeric
fragmentation.
The luteal phase was supported with the administra-
tion of 33 mg/day of natural progesterone starting from
pick-up day and then 50 mg/day from embryo transfer
day. Serum levels of hCG were measured 14 days after
embryo transfer and, if positive, were obtained every 3–6
days until an intrauterine gestational sac was demon-
strated by US examination.
The main goal of the study was the definition of the
number and the quality of the oocytes retrieved; in par-
ticular the rates of M2 oocytes and unsuitable oocytes
(only zona, M1 oocytes, germinal vescicle and degenerated
oocytes) were evaluated.
Secondary endpoints were the Ovarian Sensitivity Index
(OSI: n° oocytes retrieved/total Gonadotropin units × 1000),
oestradiol levels at the day of hGC administration,
fertilization rate, implantation rate, ongoing pregnancy rate.
Statistical analysis
Data were analysed using the Statistical Package for the
Social Science (SPSS Release 16.0.2; SPSS Inc., Chicago, IL).
Continous variables were presented as mean and SD. Statis-
tical analysis was performed using an unpaired t-test
for independent data and t-test, setting the significance
level at p ≤ 0.05.
Results
Group A and B were homogeneous for age and causes
of infertility of their members. Baseline characteristics of
patients were similar (Table 1). There was no significantdifference between the two groups regarding oestradiol
level, but total rec-FSH units were significantly lower in
group A (1975 ± 298 vs 2212 ± 312, p = 0.004) (Table 2).
The mean number of oocytes retrieved was similar in
the two study groups, but the results show a statistically
significant increase of M2 oocytes rate in group A (80.5 %
vs 66.6 %, p = 0.01). The rate of oocytes that did not show
the suitable features for insemination (only zona, M1
oocytes, germinal vescicle and degenerated oocytes) was
statistically significantly lower in group A (19.4 % vs 33.3 %
p = 0.01) (Table 3). The fertilization rate (87 % vs 84 %),
implantation rate (10.8 % vs 9 %), grade 1 embryos rate
(87.9 % vs 81.9 %) and pregnancy rate (18.4 % vs 15.7 %)
showed a positive trend in patients pretreated with MI,
without reaching a statistical significance (Table 3).
The ovarian sensitivity index was higher, reaching a
statistical significance, in the group of patients pre-treated
with MI plus folic acid than in the control group (1.88 ±
0.81 vs 1.54 ± 0.65, p < 0.05), showing an improvement in
ovarian sensibility to gonadotropin (Table2).
Discussion
This pilot study evaluates the impact that a treatment
with MI could have on patients commonly defined poor
responders on the outcome of IVF cycles.
The fertilization rate, implantation rate, grade 1 em-
bryos rate and pregnancy rate showed a positive trend in
patients pretreated with MI, without reaching a statis-
tical significance.
The results suggest that MI therapy is associated to an
increase in M2 oocytes retrieved number and in ovarian
sensitivity to gonadotropins in poor responders, in which
IVF is burdened by high dosages of gonadotropins and
Table 3 Oocytes quality, embryo characteristics and clinical
outcome
Group A Group B p
No. of oocytes M2 (%) 80,5 % 66.6 % <0.05
No. of not suitable oocytesa (%) 19,4 % 33.3 % <0.05
Fertilization rate (%) 87 % 84 % n.s
Implantation rate (%) 10,8 % 9 % n.s.
Grade I embryo rate (%) 87.9 % 81,9 % n.s
Pregnancy rate (%) 18,4 % 15.7 % n.s.
aM1, Germinal Vescicle, only zona and degenerated oocytes
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the results of the technique.
The first study about the role of MI in in-vitro human
fertilization (IVF) dates back to 1992. Such study reported
an elevated level of inositol in serum samples of patients
having successful IVF pregnancies, thus indicating a pos-
sible involvement of inositol in both the early in vitro
phase of IVF and the maintenance of normal embryonic
development [20]. A later study demonstrated that a
higher concentration of MI in human follicular fluid posi-
tively correlates with good oocytes quality [21].
Furthermore, it was demonstrated that supplementa-
tion with MI is positively related to meiotic progression
of mouse germinal vesicle oocytes, through the enhance-
ment of intracellular calcium oscillation [22].
Previous experiences had already shown the beneficial
effects of MI-based treatment on oocyte quality in PCO
women, suggesting a possible beneficial effect of MI on
oocyte competence and maturation [13, 23].
The beneficial effect of the co-treatment with inositol
and melatonin in managing patients with a low oocyte
quality in IVF cycles [17] has been also shown, even if no
potential positive effect–directly related to inositol–for
poor responding patients has been proven so far.
However, this pilot study has some limitations: the num-
ber of patients involved is too small to offer a great signifi-
cance of the result obtained and we have not analyzed
other potential factors that may have affected the differ-
ences in ovarian sensitivity (as polymorphisms of FSH
receptor).
Conclusion
In conclusion, our results, related to other study reported
above, suggest that MI could plays a role in oocyte matur-
ation and competence, and its concentration could even
influence cellular homeostasis.
Although MI supplementation had not a statistical sig-
nificance effect on pregnancy rate, the group pre-treated
with MI showed a significant increase of the gonado-
tropin ovarian sensitivity index (OSI), resulting from the
ratio between the number of oocytes obtained and the
unities of gonadotropin used. This latter result suggestsa new role for MI in the intracellular signal-transduction
pathways mediated by the gonadotropin receptor, sup-
porting the development of new research perspectives
and new therapeutic strategies for the management of
poor-responders patients. Additional, larger randomized
controlled studies are needed to reinforce our prelimin-
ary findings.
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Capsule
Myo-inositol therapy seems to be helpful in “poor responders” patients
undergoing IVF cycles, improving oocyte quality and ovarian sensitivity to
gonadotropin.
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